NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.

Which TKI is used in NSCLC and requires the presence of an EGFR mutation?

Erlotinib (Tarceva)
Brigatinib (Alunbrig)
Imatinib (Gleevec)
Dasatinib

The correct answer is: Erlotinib (Tarceva)

Erlotinib (Tarceva) is the correct answer because it is a tyrosine kinase inhibitor (TKI) that is specifically used in non-small cell lung cancer (NSCLC) and requires the presence of an EGFR mutation. Erlotinib works by targeting and inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which is often overactive in certain types of cancer, including NSCLC with EGFR mutations. This targeted therapy helps to slow down the growth and spread of cancer cells in NSCLC patients with EGFR mutations. The other options are incorrect: - Brigatinib (Alunbrig) is also a TKI used in NSCLC, but it is not specifically known to require the presence of an EGFR mutation. - Imatinib (Gleevec) is a TKI used in the treatment of chronic myeloid leukemia (CML) and certain types of gastrointestinal stromal tumors (GISTs), not NSCLC. - Dasatinib is another TKI primarily used in the treatment of CML and acute lymphoblastic leukemia, not NSCLC with EGFR mutations.